# A Phase II Trial Comparing Gemcitabine and Pazopanib Versus Gemcitabine and Docetaxel for Patients With Advanced Soft Tissue Sarcoma

> **NCT01593748** · PHASE2 · COMPLETED · sponsor: **Medical University of South Carolina** · enrollment: 90 (actual)

## Conditions studied

- Sarcoma

## Interventions

- **DRUG:** Gemcitabine and Pazopanib
- **DRUG:** Gemcitabine and Docetaxel

## Key facts

- **NCT ID:** NCT01593748
- **Lead sponsor:** Medical University of South Carolina
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-09-27
- **Primary completion:** 2019-04-24
- **Final completion:** 2019-04-24
- **Target enrollment:** 90 (ACTUAL)
- **Last updated:** 2020-04-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01593748

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01593748, "A Phase II Trial Comparing Gemcitabine and Pazopanib Versus Gemcitabine and Docetaxel for Patients With Advanced Soft Tissue Sarcoma". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT01593748. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*